Chiang Mai University HIV/AIDS Clinical Trials Unit

清迈大学艾滋病毒/艾滋病临床试验单位

• 批准号: 7384989
• 负责人: THIRA SIRISANTHANA
• 金额: $ 193.48万
• 依托单位: CHIANG MAI UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-15 至 2014-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7384989
• 关键词: AIDS clinical trial group; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Adolescent; Asia; Blood donor; Category Rating Scale; Child; China; Clinic; Clinical; Clinical Management; Clinical Trials; Clinical Trials Cooperative Group; Communicable Diseases; Communities; Country; County; Couples; Discipline of obstetrics; Disease Marker; Epidemic; Faculty; Foundations; Grant; HIV; HIV Infections; HIV vaccine; Health Sciences; Housing; India; Injecting drug user; Laboratories; Lead; Medicine; Military Personnel; Monitor; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; National Institute of Drug Abuse; National Institute of Mental Health; Patients; Pharmacy facility; Population; Pregnant Women; Principal Investigator; Process; Public Health; Research; Research Infrastructure; Research Institute; Research Priority; Research Project Grants; Resources; Shipping; Ships; Site; Thailand; Translational Research; Universities; Vertical Disease Transmission; Vietnam; Walking; World Health Organization; clinical research site; data management; epidemiology study; experience; male; sample collection; sex

DESCRIPTION (provided by applicant): Chiang Mai University (CMU), Thailand, is proposing to establish the CMU HIV/AIDS Clinical Trials Unit, Thira Sirisanthana, Principal Investigator. The CMU CTU consists of an administrative component located at the Research Institute for Health Sciences (RIHES), CMU, where the main resources for specimen collection, processing and shipping, clinical laboratory assessments, data management, pharmacy, regulatory compliance, fiscal management and administration are housed. Clinical facilities within walking distance are located at the Faculty of Medicine, CMU. This CTU will have 3 Clinical Research Sites (CRSs), the GMU AIDS Clinical Trials Group Clinical Research Site (CMU ACTG CRS), Khuanchai Supparatpinyo, site leader, affiliated with the newly formed Aids Clinical Trials Group (ACTG) network; the HIV Vaccine Trial Network Clinical Research Site (CMU HVTN CRS), Vinai Suriyanon, site leader, affiliated with the newly formed HIV Vaccine Trial Network (HVTN); and the Pediatrics-Obstetrics Clinical Research Site (CMU PEDOB CRS), Virat Sirisanthana, site leader, which will focus on research priorities in mother-to-child transmission of HIV, as well as optimization of clinical management and translational research in children, adolescents, and pregnant women. RIHES and its collaborators began research in HIV/AIDS in 1988 in studios mounted to monitor infectious disease markers among blood donors. In 1991 with a grant from the Rockefeller Foundation, RIHES studied the epidemiology of HIV infection in military conscripts and later expanded to include other populations, such as sex workers, STD clinic patients, IDUs, non-injecting drug users, factory workers, couples with an infected male partner, and community populations. Collaborative partnership have been formed with the Johns Hopkins University, the Royal Thai Army and the Ministry of Public Health. Research grant support has come from NIAID, NICHD, NIDA, NIMH, CDC/CONRAD, AIDSCAP/USAID, WRAIR, WHO, and the Rockefeller Foundation. Thailand was the first country in Asia with a major AIDS epidemic. The Thai epidemic curve leads those in India, China, and Vietnam by 5 - 10 years. With the countries of Asia having similar culture, Thailand has the infrastructure and the experience to lead them in the HIV/AIDS prevention and treatment research. Finally, Thailand is perhaps the only county in the world where the CRF_01 AE form of HIV can be optimally studied. ADMINISTRATIVE COMPONENT:

描述（由申请人提供）：泰国Chiang Mai大学（CMU）提议建立CMU HIV/AIDS临床试验部门，首席研究员Thira Sirisanthana。 CMU CTU由CMU研究所研究所（RIHES）的行政组成部分组成，那里是标本收集，加工和运输的主要资源，临床实验室评估，数据管理，药物，药房，法规合规性，财务管理和管理。步行距离内的临床设施位于CMU医学学院。该CTU将有3个临床研究地点（CRS），GMU AIDS临床试验组临床研究地点（CMU ACTG C​​RS），现场负责人Khuanchai Specaratpinyo，隶属于新成立的艾滋病临床试验小组（ACTG）网络；现场负责人Vinai Suriyanon的HIV疫苗试验网络临床研究地点（CMU HVTN CRS）与新成立的HIV疫苗试验网络（HVTN）相关；以及儿科 - 孔子临床研究地点（CMU PEDOB CRS），现场负责人Virat Sirisanthana，该研究将重点介绍HIV母亲到儿童传播的研究重点，以及对儿童，青少年和孕妇的临床管理和翻译研究的优化。 RIHES及其合作者于1988年开始在艾滋病毒/艾滋病研究的工作室中进行研究，以监测献血者中的传染病标记。 1991年，Rihes获得了洛克菲勒基金会（Rockefeller Foundation）的赠款，研究了军事征兵中艾滋病毒感染的流行病学，后来扩展到包括其他人群，例如性工作者，性病诊所患者，IDUS，IDUS，非注射吸毒者，工厂工人，夫妇，有感染的男性伴侣和社区人群。与约翰·霍普金斯大学，皇家泰国军队和公共卫生部建立了合作伙伴关系。研究赠款的支持来自NIAID，NICHD，NIDA，NIMH，CDC/CONRAD，AIDSCAP/USAID，WRAIR，WHO WHO和ROCKEFELLER基金会。泰国是亚洲第一个拥有主要艾滋病流行病的国家。泰国流行曲线将印度，中国和越南的人带领5至10年。 随着亚洲国家具有相似文化的国家，泰国拥有基础设施和带领他们在艾滋病毒/艾滋病预防和治疗研究中的经验。最后，泰国也许是世界上唯一可以最佳地研究CRF_01 AE形式的县。 管理组件：